Accessibility
Focus on underserved treatment areas
Orexo targets opioid use disorder (OUD), a long-overlooked treatment area, through the products Zubsolv® and MODIA®.
Healthcare provider education
Orexo combats stigma by educating healthcare providers (HCPs) and the public about OUD as a medical condition. In 2024, its sales team engaged in over 42,000 educational interactions with HCPs.
Patient and provider support
The MATCore® program integrates Orexo’s OUD treatment portfolio with education and outreach to reach even the most marginalized populations.
Product innovation
Orexo is expanding its treatment options, including OX124, a high-dose naloxone rescue medication for opioid overdoses. Although delayed due to regulatory requirements coupled to commercial manufacturing, it addresses an unmet need.
The next-generation formulation technology, AmorphOX®, enhances the chemical and physical stability of substances that typically degrade over time. This improved stability can reduce logistical complexity by eliminating the need for cold chain storage, ultimately contributing to reach more patients through more efficient and resilient supply chains.
Affordability
Offering patient assistant programs
To reach financial vulnerable individuals, Orexo provides three patient assistant programs. These programs are
Medicaid reimbursement progress
Medicaid coverage for Zubsolv® has grown from 30% to 50% during the last years, expanding access for lower-income patients.
Private insurance coverage: 98% of privately insured patients are eligible for reimbursement, demonstrating strong financial accessibility.
You are now leaving the Orexo AB (publ.) corporate website at orexo.com to visit the Orexo US, Inc. website at us.orexo.com.
